Honeybear Biosciences Shines at the 2025 Taiwan Biotech Forum CoNectar® Technology Wows the Audience and Perfectly Crystalizes the Brand Spirit of Honeybear Read more
CEO Dr. Chuang, Simon, Shih-Hsien, Attends World ADC Asia Presented Latest ARC Research Results and Received Highly Regard Read more
Dr. Sun, Wei-Ting Delivers Invited Lecture at TMU, Offering In-Depth Analysis of ADC Development Trends Honeybear’s Unique CoNectar® Platform Draws Lots of Attention Read more
HoneyBear Biosciences and A*STAR Team Successfully Complete Two Licensing Agreements in Singapore Read more
Dr. Chuang, Simon, Shih-Hsien, CEO of HoneyBear Biosciences, invited to give a speech at ADC Congress Asia Read more
Special Interview on Startup 101—"Next-Generation Cancer Drug Platform, Becoming a Lifeline for Patients: Interview with HoneyBear Biosciences" Read more
“Process For Preparing Glycoprotein-Drug Conjugates”awarded with Silver award of the 8th National invention and creation award granted by Ministry of Economic Affairs. Read more
Simon Shih-Hsien Chuang, CEO of Honeybear Biosciences invited to give a speech in 2023 BioAsia Read more
“First ADC drug with dual anti-cancer effects worldwide” press conference on March 13th, 2023 Read more
